IRIS Accounts Production v25.2.0.378 SC776701 Board of Directors 24.7.23 31.12.24 31.12.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhSC7767012023-07-23SC7767012024-12-31SC7767012023-07-242024-12-31SC7767012023-07-23SC776701ns14:PoundSterling2023-07-242024-12-31SC776701ns10:Director12023-07-242024-12-31SC776701ns10:PrivateLimitedCompanyLtd2023-07-242024-12-31SC776701ns10:SmallEntities2023-07-242024-12-31SC776701ns10:AuditExempt-NoAccountantsReport2023-07-242024-12-31SC776701ns10:SmallCompaniesRegimeForDirectorsReport2023-07-242024-12-31SC776701ns10:SmallCompaniesRegimeForAccounts2023-07-242024-12-31SC776701ns10:FullAccounts2023-07-242024-12-31SC77670112023-07-242024-12-31SC776701ns5:CurrentFinancialInstruments2024-12-31SC776701ns5:ShareCapital2024-12-31SC776701ns5:RetainedEarningsAccumulatedLosses2024-12-31SC776701ns5:IntangibleAssetsOtherThanGoodwill2023-07-242024-12-31SC776701ns5:PatentsTrademarksLicencesConcessionsSimilar2023-07-242024-12-31SC776701ns5:ComputerSoftware2023-07-242024-12-31SC776701ns5:PlantMachinery2023-07-242024-12-31SC776701ns5:IntangibleAssetsOtherThanGoodwill2024-12-31SC776701ns5:PlantMachinery2024-12-31SC776701ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-31SC776701ns5:WithinOneYear2024-12-31SC776701ns5:BetweenOneFiveYears2024-12-31SC776701ns5:MoreThanFiveYears2024-12-31SC776701ns5:AllPeriods2024-12-31
REGISTERED NUMBER: SC776701















REDOX HEALTH LTD

UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD 24 JULY 2023 TO 31 DECEMBER 2024






REDOX HEALTH LTD (REGISTERED NUMBER: SC776701)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE PERIOD 24 JULY 2023 TO 31 DECEMBER 2024




Page

Balance Sheet 1

Notes to the Financial Statements 3


REDOX HEALTH LTD (REGISTERED NUMBER: SC776701)

BALANCE SHEET
31 DECEMBER 2024

Notes £    £   
FIXED ASSETS
Intangible assets 4 21,989
Tangible assets 5 230,030
252,019

CURRENT ASSETS
Debtors 6 69,995
Cash at bank 6,662
76,657
CREDITORS
Amounts falling due within one year 7 395,417
NET CURRENT LIABILITIES (318,760 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(66,741

)

CAPITAL AND RESERVES
Called up share capital 100
Retained earnings (66,841 )
(66,741 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

REDOX HEALTH LTD (REGISTERED NUMBER: SC776701)

BALANCE SHEET - continued
31 DECEMBER 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 24 September 2025 and were signed on its behalf by:





J Fields - Director


REDOX HEALTH LTD (REGISTERED NUMBER: SC776701)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD 24 JULY 2023 TO 31 DECEMBER 2024

1. STATUTORY INFORMATION

Redox Health Ltd is a private company, limited by shares, registered in Scotland. The company's registered office is 5 Fitzroy Place, Glasgow, G3 7RH.

The presentation currency of the financial statements is Sterling (£).

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of the Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. There were no material departures from this standard. The financial statements have been prepared under the historical cost convention.

Going Concern
The financial statements have been prepared on a going concern basis. The Directors have confirmed ongoing financial support and will not seek loan repayment for at least 12 months from the accounts approval date, in order to support initial trading and working capital. Based on this funding and the company's business plan, directors expect the company has adequate resources for the foreseeable future.

Judgements
The company considers on an annual basis the judgements that are made by management when applying its significant accounting policies that would have the most significant effect on amounts that are recognised in the financial statements. The directors consider there are no such significant judgements.

Turnover
Turnover represents net invoiced sales of goods and services excluding value added tax. The company's policy is to recognise income at the point of sale of goods and of holistic services when substantively all the risks and rewards in connection with the goods and services have been passed to the buyer.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of three years.

Computer software is being amortised evenly over its estimated useful life of three years.

Due to the short period of trading the directors consider it appropriate to commence amortisation from 01 January 2025.

REDOX HEALTH LTD (REGISTERED NUMBER: SC776701)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 24 JULY 2023 TO 31 DECEMBER 2024

2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on reducing balance and straight line over life of lease

Tangible fixed assets are included at cost less accumulated depreciation and accumulated impairment losses. Due to the short period the assets were in use,the directors consider it appropriate to commence depreciation from 01 January 2025.

Impairment of non-financial assets
At each reporting date non-financial assets not carried at fair value, like improvements to property and plant & equipment, are reviewed to determine whether there is an indication that an asset may be impaired. If there is an indication of possible impairment, the recoverable amount which is the higher of value in use and the fair value less cost to sell, is estimated and compared with the carrying amount. If the recoverable amount is lower, the carrying amount of the asset is reduced to its recoverable amount and an impairment loss is recognised immediately in profit and loss.

Financial instruments
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and loans from related parties.

Debt instruments like loans and other accounts receivable and payable are initially measured at present value of future payments and subsequently, amortised cost using the effective interest method.
Debt instruments that are payable or receivable within one year, typically trade debtors and trade creditors, are measured, initially and subsequently, at the undiscounted amount of cash or other consideration expected to be paid or received.

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for evidence of impairment and if found, an impairment loss is recognised in profit or loss. Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Cash and cash equivalents includes cash in hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. Bank overdrafts, when applicable, are shown within borrowings in current liabilities.

Taxation
Taxation represents the sum of tax currently payable and deferred tax. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

The charge for taxation takes into account taxation deferred as a result of timing differences between the treatment of certain items for taxation and accounting purposes. In general, deferred taxation is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. However, deferred tax assets are recognised only to the extent that the directors consider that it is more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted. Deferred taxation is measured on a non-discounted basis at the tax rates that are expected to apply in the periods in which the timing differences reverse, based on tax rates and laws enacted or substantively enacted at the balance sheet date.

With the exception of changes arising on the initial recognition of a business combination, the tax expense is presented either in profit or loss, other comprehensive income or statement of changes in equity depending on the transaction that resulted in the tax expense.

Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors.

REDOX HEALTH LTD (REGISTERED NUMBER: SC776701)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 24 JULY 2023 TO 31 DECEMBER 2024

2. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
Company contributions are paid in respect of a scheme set up for auto-enrolment purposes. Contributions payable to the scheme are charged to Profit and Loss Account in the period to which they relate.

Provisions
Provisions are recognised when the company has a legal or constructive obligation at the reporting date as a result of a past event, it is probable that the company will be required to settle the obligation and the amount of the obligation can be reliably estimated. Provisions are recognised at the best estimate of the amount required to settle the obligation at the reporting date.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 2 .

4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
Additions 21,989
At 31 December 2024 21,989
NET BOOK VALUE
At 31 December 2024 21,989

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
Additions 230,030
At 31 December 2024 230,030
NET BOOK VALUE
At 31 December 2024 230,030

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Other debtors 69,995

REDOX HEALTH LTD (REGISTERED NUMBER: SC776701)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 24 JULY 2023 TO 31 DECEMBER 2024

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Trade creditors 532
Other creditors 394,885
395,417

8. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
£   
Within one year 17,000
Between one and five years 68,000
In more than five years 32,583
117,583

9. RELATED PARTY DISCLOSURES

Included in creditors at the balance sheet date is a loan of £391,568 from a director. Although the balance due in less than one year is technically repayable on demand, the director has confirmed to the company that he does not intend to seek repayment of this loan, for at least a period of twelve months from the date of approval of these financial statements.